Company Profile

Hepregen Corporation (AKA: Ascendance Biotechnology~)
Profile last edited on: 4/9/19      CAGE: 4X2Z2      UEI:

Business Identifier: Advanced toxicity screening and drug discovery
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

200 Boston Avenue Suite 1500
Medford, MA 02155
   (781) 391-0205
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

In November 2015, Hepregen Corporation and the ESI BIO products division of BioTime Inc. merged to form a multinational cell-based assay company. doing business as Ascendance. In March 2018, BioIVT, a provider of biospecimens and related services, acquired Ascendance Biotechnology, Inc. Hepregen Corporation had originally been developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. With its high fidelity model of the human liver, Hepregen's bioengineered solution was designed to improve predictivity of how drugs will affect the liver once in humans. This company ihadbeen spinout of the 2006 project desinated Human liver models for faster, safer drug development which was supported by the MIT Deshpande Center for Technological Innovation. HepatoPac, a bio-engineered micro-liver platform for use in a range of applications, including metabolite identification, toxicity screening, clearance, drug-drug interactions, transporter involvement, in silico models, toxicogenomics, and disease modeling applications in humans. The firm's capabilities are also used in cosmetic and environmental testing industries.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Bernadette (Bonnie) C Fendrock -- Co-Founder and President

  Vincent Zurawski -- Chief Executive Officer

  Michael Holsapple -- Vice President of Toxicology Product Development

  Salman Khetani -- Director, Research

  John (Jack) McGeehan -- Vice President, Operations

  Mann Shoffner -- Director, Marketing and Sales